Literature DB >> 30267743

Aptamer-guided nanomedicines for anticancer drug delivery.

Walhan Alshaer1, Hervé Hillaireau2, Elias Fattal3.   

Abstract

Aptamers are versatile nucleic acid-based macromolecules characterized by their high affinity and specificity to a specific target. Taking advantage of such binding properties, several aptamers have been selected to bind tumor biomarkers and have been used as targeting ligands for the functionalization of nanomedicines. Different functionalization methods have been used to link aptamers to the surface drug nanocarriers. The pre-clinical data of such nanomedicines overall show an enhanced and selective delivery of therapeutic payloads to cancer cells, thereby accelerating steps towards more effective therapeutic systems. This review describes the current advances in the use of aptamers as targeting moieties for the delivery of therapeutic and imaging agents to tumors by conjugation to organic and inorganic nanocarriers.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aptamers; Cancer; Liposomes; Micelles; Nanocarriers; Nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 30267743     DOI: 10.1016/j.addr.2018.09.011

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  36 in total

Review 1.  Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications.

Authors:  Qun Guan; Guang-Bo Wang; Le-Le Zhou; Wen-Yan Li; Yu-Bin Dong
Journal:  Nanoscale Adv       Date:  2020-07-16

Review 2.  Aptamer-Based Cancer Cell Analysis and Treatment.

Authors:  Limei Wu; Yutong Zhang; Zhimin Wang; Yue Zhang; Jianmei Zou; Liping Qiu
Journal:  ChemistryOpen       Date:  2022-10       Impact factor: 2.630

Review 3.  Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Authors:  Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2019-04-22       Impact factor: 6.648

4.  Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.

Authors:  Xiao Liang; Yudi Wang; Hui Shi; Mengmeng Dong; Haobo Han; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2021-03-30

Review 5.  Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy.

Authors:  Ki-Taek Kim; Jae-Young Lee; Dae-Duk Kim; In-Soo Yoon; Hyun-Jong Cho
Journal:  Pharmaceutics       Date:  2019-06-14       Impact factor: 6.321

Review 6.  A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy.

Authors:  Min Woo Kim; Seung-Hae Kwon; Jung Hoon Choi; Aeju Lee
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

7.  Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel.

Authors:  Fadwa Odeh; Randa Naffa; Hanan Azzam; Ismail S Mahmoud; Walhan Alshaer; Abeer Al Bawab; Said Ismail
Journal:  Heliyon       Date:  2019-11-27

Review 8.  Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy.

Authors:  Zhaoying Fu; Jim Xiang
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

Review 9.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07

Review 10.  Aptamers: Cutting edge of cancer therapies.

Authors:  Sarah Shigdar; Brett Schrand; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2021-06-17       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.